(Q54766181)

English

Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

0 references

1 reference

based on heuristic

inferred from title

author name string

H L Y Chan

1

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

Y C Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

E J Gane

3

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

S K Sarin

4

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

D J Suh

5

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

T Piratvisuth

6

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

B Prabhakar

7

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

S G Hwang

8

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

G Choudhuri

9

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

R Safadi

10

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

T Tanwandee

11

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

A Chutaputti

12

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

C Yurdaydin

13

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

W Bao

14

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

C Avila

15

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

A Trylesinski

16

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

publication date

15 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

19

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

10

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

732-743

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

Cost analysis of adult–adult living donor liver transplantation in Tokyo University Hospital

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Tenofovir-related nephrotoxicity: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Management of patients with decompensated HBV cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

A new equation to estimate glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01600.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2012.01600.X

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/22967105

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54766181&oldid=1584896314"